Pfizer Pain Cutback Shutters UK R&D Site
This article was originally published in Scrip
Pfizer, Inc. is cutting back its investment in early R&D into pain, and as a result will close its Neusentis research facility in Cambridge, UK. The move will result in the loss of up to 120 jobs.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.